Centre for Investigative and Diagnostic Oncology · Dr. Peter Highfield Zilico Ltd. (Diagnostic...
1
Centre for Investigative and Diagnostic Oncology More than a quarter of a million people are diagnosed with cancer in the UK every year and doctors have estimated that cancer will affect one in three people at some point in their lives. Our approach The main areas we are focused on are: ‰ Early diagnosis ‰ Vital imaging technology ‰ New cancer therapies Our Research Centre In 2008, Middlesex University established the Centre in the new Hatchcroft building. Our people and their projects Under the overall direction of the eminent immunologist, Professor Ivan Roitt FRS, the Research Centre comprises a network of internationally renowned scientists (see below). Electrical Impedance Tomography (EIT) Led by Professor Richard Bayford (the international pioneer at the forefront of this ground-breaking technology), EIT is a very economical and non- invasive technique for imaging which involves placing a series of electrodes on the body surface and analysing the minute currents that flow between them to reveal abnormal cell structures such as tumours. Research on imaging of breast cancers has been very encouraging. We are developing a small EIT device for detection of colorectal and prostate cancers. Professor Bayford is already using EIT to image and monitor neo-natal lung function. New cancer therapies We intend to use minute gold nanoparticles and liposomes targeted to bind specifically to tumour cells to deliver cancer drugs directly to the tumour to limit any harmful side-effects caused by toxic chemotherapeutic drugs. We are particularly interested in colorectal and prostate cancers. We wish to study the potential for tumour ablation by applying an external energy field to targeted magnetic nanoparticles. Screening for early cancer Professor Roitt and his team are developing diagnostic microassays each providing multiple tests for serum protein biomarkers or their autoantibodies. Combined with tests on DNA and analysis of the spectrum of low molecular weight breakdown products, unique combinations of the results should identify the individuals at risk accurately. Cancer vaccines Dr. Stephen Butler is particularly interested in the involvement of the pregnancy hormone, hCG, in the autocrine growth of bladder cancer cell lines. He is developing a novel cancer vaccine which would evoke antibodies capable of neutralising these growth factors. Viruses and cancer Professor Stephen Dilworth’s Virus Group is centred on identifying new viruses that may be involved in forming cancers, and then establishing vaccination procedures to prevent this. Using animal viruses they have identified a new protein complex involved in switching on cancer cell growth. Inhibition of this protein cluster could lead to development of anti-cancer drugs. An arsenical anti-cancer drug We have found that arsenic trioxide, can inhibit expression of a key protein and produces programmed cell death in cells infected with human papilloma virus which is directly associated with cervical cancer. We wish to unravel this process to see how it can be exploited for therapeutic purposes. We are investigating the possible implication of this virus in other types of tumour. The benefits of our work Tangible benefits should include: ‰ Faster and more efficient diagnosis ‰ Improved monitoring of the efficacy of cancer treatments ‰ More effective new cancer therapies ‰ Reduction in costs of diagnosis ‰ Offering diagnosis to a wider community, particularly in poorer areas Design: www.worksong.co.uk 12.12 Middlesex University Cancer Research Scientific Staff Professor Ivan Roitt Director of Centre Professor Richard Bayford Professor of Bio- Modelling & Informatics Professor Stephen Dilworth Professor of Cancer Cell Biology Dr. Andrew Tizzard Reader in Bio-Engineering Dr. Ajit Shah Reader in Bio-Analytical Science Dr. Stephen Butler Reader in Biomedical Diagnostics Dr. Lucy Ghali Senior Lecturer in Molecular & Cellular Biology Dr. Christopher Ring Senior Lecturer in Microbiology Dr. Frank Hills Senior Lecturer in Clinical Biochemistry & Proteomics Dr. Mahmoud Nasse Lecturer in Biochemistry Dr. Song Wen Lecturer in Cell Biology Dr. Torben Lund Senior Research Fellow in Cell Biology l to r: Dr Stephen Butler, Professor Richard Bayford, Professor Stephen Dilworth and Professor Ivan Roitt. External Consultant Associates Professor the Lord Darzi Consultant & Head, Division of Surgery (Imperial NHS Trust) Professor Angus Dalgleish Consultant Oncologist (St. George’s Hosp. Med. Schl.) Professor Justin Stebbing Consultant Oncologist (Imperial NHS Trust) Dr. Patrizia Cohen Consultant Histopathologist (Imperial NHS Trust) Professor Kerry Chester Consultant Immunologist (University College London) Professor Thomas Rademacher C.E.O. Midatech Ltd. (Gold Nanoparticle company) Mr. Raj Persad Consultant Urology Surgeon Mr. Keyoumars Ashkan Consultant Surgeon (King’s College) Dr. Atif Agaiby Consultant Dermatologist (Northwick Park Hospital) Dr. Peter Highfield Zilico Ltd. (Diagnostic Impedance Devices company) Dr. Andreas Demosthenous Reader in analogue and biomedical electronics (U.C.L.) A2 poster 2_2_Layout 1 12/12/2012 16:38 Page 1
Transcript of Centre for Investigative and Diagnostic Oncology · Dr. Peter Highfield Zilico Ltd. (Diagnostic...
Centre for Investigative and Diagnostic Oncology
More than a quarter of a million people arediagnosed with cancer in the UK every year anddoctors have estimated that cancer will affect one inthree people at some point in their lives.
Our approach The main areas we are focused on are:‰ Early diagnosis‰ Vital imaging technology‰ New cancer therapies
Our Research CentreIn 2008, Middlesex University established the Centrein the new Hatchcroft building.
Our people and their projectsUnder the overall direction of the eminentimmunologist, Professor Ivan Roitt FRS, theResearch Centre comprises a network ofinternationally renowned scientists (see below).
Electrical ImpedanceTomography (EIT)Led by ProfessorRichard Bayford (theinternational pioneer atthe forefront of thisground-breakingtechnology), EIT is a veryeconomical and non-invasive technique forimaging which involvesplacing a series ofelectrodes on the bodysurface and analysing theminute currents that flow
between them to reveal abnormal cell structuressuch as tumours.
Research on imaging of breast cancers has beenvery encouraging. We are developing a small EITdevice for detection of colorectal and prostatecancers. Professor Bayford is already using EIT toimage and monitor neo-natal lung function.
New cancer therapiesWe intend to use minute gold nanoparticles andliposomes targeted to bind specifically to tumourcells to deliver cancer drugs directly to the tumour tolimit any harmful side-effects caused by toxicchemotherapeutic drugs. We are particularlyinterested in colorectal and prostate cancers.
We wish to study the potential for tumour ablation byapplying an external energy field to targetedmagnetic nanoparticles.
Screening for early cancerProfessor Roitt and his team are developingdiagnostic microassays each providing multiple testsfor serum protein biomarkers or their autoantibodies.Combined with tests on DNA and analysis of thespectrum of low molecular weight breakdownproducts, unique combinations of the results shouldidentify the individuals at risk accurately.
Cancer vaccinesDr. Stephen Butler is particularly interested in theinvolvement of the pregnancy hormone, hCG, in theautocrine growth of bladder cancer cell lines. He isdeveloping a novel cancer vaccine which wouldevoke antibodies capable of neutralising thesegrowth factors.
Viruses and cancerProfessor Stephen Dilworth’s Virus Group iscentred on identifying new viruses that may beinvolved in forming cancers, and then establishingvaccination procedures to prevent this.
Using animal viruses they have identified a newprotein complex involved in switching on cancer cellgrowth. Inhibition of this protein cluster could lead todevelopment of anti-cancer drugs.
An arsenical anti-cancer drugWe have found that arsenic trioxide, can inhibitexpression of a key protein and producesprogrammed cell death in cells infected with humanpapilloma virus which is directly associated withcervical cancer.
We wish to unravel this process to see how it can beexploited for therapeutic purposes.
We are investigating the possible implication of thisvirus in other types of tumour.
The benefits of our workTangible benefits should include:‰ Faster and more efficient diagnosis‰ Improved monitoring of the efficacy of
cancer treatments‰ More effective new cancer therapies‰ Reduction in costs of diagnosis‰ Offering diagnosis to a wider community,
particularly in poorer areas
Desi
gn: w
ww
.wor
kson
g.co
.uk
12.1
2
Middlesex University Cancer Research Scientific StaffProfessor Ivan Roitt Director of CentreProfessor Richard Bayford Professor of Bio- Modelling & Informatics Professor Stephen Dilworth Professor of Cancer Cell BiologyDr. Andrew Tizzard Reader in Bio-EngineeringDr. Ajit Shah Reader in Bio-Analytical ScienceDr. Stephen Butler Reader in Biomedical DiagnosticsDr. Lucy Ghali Senior Lecturer in Molecular & Cellular BiologyDr. Christopher Ring Senior Lecturer in MicrobiologyDr. Frank Hills Senior Lecturer in Clinical Biochemistry & ProteomicsDr. Mahmoud Nasse Lecturer in BiochemistryDr. Song Wen Lecturer in Cell BiologyDr. Torben Lund Senior Research Fellow in Cell Biology
l to r: Dr Stephen Butler, Professor Richard Bayford,Professor Stephen Dilworth and Professor Ivan Roitt.
External Consultant AssociatesProfessor the Lord Darzi Consultant & Head, Division of Surgery (Imperial NHS Trust)Professor Angus Dalgleish Consultant Oncologist (St. George’s Hosp. Med. Schl.)Professor Justin Stebbing Consultant Oncologist (Imperial NHS Trust)Dr. Patrizia Cohen Consultant Histopathologist (Imperial NHS Trust)Professor Kerry Chester Consultant Immunologist (University College London)Professor Thomas Rademacher C.E.O. Midatech Ltd. (Gold Nanoparticle company)Mr. Raj Persad Consultant Urology SurgeonMr. Keyoumars Ashkan Consultant Surgeon (King’s College)Dr. Atif Agaiby Consultant Dermatologist (Northwick Park Hospital)Dr. Peter Highfield Zilico Ltd. (Diagnostic Impedance Devices company)Dr. Andreas Demosthenous Reader in analogue and biomedical electronics (U.C.L.)
A2 poster 2_2_Layout 1 12/12/2012 16:38 Page 1
